Group 1 | Group 2 | Group 3 | Total | p# value | ||
---|---|---|---|---|---|---|
PSH | PSH + IPH | PSH + IPH + VH | ||||
(na = 4) | (n = 17) | (n = 17) | (n = 38) | |||
Age (years) | ||||||
Mean ± SD | 18.75 ± 7.50 | 22.12 ± 8.89 | 18.29 ± 5.60 | 20.05 ± 7.47 | ptotal | 0.315 |
Range | 15–30 | 10–39 | 11–31 | 10–39 | ||
Gender, N (%) | ||||||
Male | 3 (75%) | 2 (11.8%) | 7 (41.2%) | 12 (31.6%)b | ||
Female | 1 (25%) | 15 (88.2%) | 10 (58.8%) | 26 (68.4%) | ||
Risk factor | 1 | 3 | 6 | 10 | ||
Male | 1 | 1 | 2 | 4c | ||
Female | 0 | 2 | 4 | 6 | ||
Myopia (Diopters) | ||||||
Mean ± SD | 2.88 ± 1.09 | 3.28 ± 1.39 | 3.57 ± 2.24 | 3.37 ± 1.77 | ptotal | 0.758 |
Range | 2.00–4.25 | 1.75–7.00 | 1.25–9.00 | 1.25–9.00 | ||
BCVA (LogMAR) | ||||||
Visit 0 (Mean ± SD) | −0.02 ± 0.11 | 0.13 ± 0.17 | 0.46 ± 0.50 | 0.26 ± 0.39 | ptotal | 0.012 |
p12 | 0.16 | |||||
p13 | 0.01 | |||||
p23 | 0.05 | |||||
Endpoint (Mean ± SD) | −0.06 ± 0.08 | −0.03 ± 0.09 | 0.01 ± 0.06 | −0.02 ± 0.08 | ptotal | 0.189 |
Duration of absorption (months) | ||||||
Mean ± SD | 2.00 ± 0.82 | 2.53 ± 1.07 | 3.59 ± 1.42 | 2.95 ± 1.33 | ptotal | 0.018 |
p13 < 0.05 | ||||||
p12 > 0.05 | ||||||
p23 > 0.05 | ||||||
Range | 1–3 | 1–4 | 2–6 | 1–6 | ||
Recurrence | 0 | 0 | 0 | 0 |